Cerestat NMDA channel blocker to block glutamate-stimulated calcium entry into neurons after injury data

CNSI presented data from a recently completed Phase II study in stroke indicating that preliminary safety data are consistent with other studies (see Clinical Status, below).

At the Stroke Society of Australasia meeting in Melbourne, the company also showed that a new MRI imaging technique, diffusion weighted imaging, demonstrated that non-treated historical controls had a median of 46 percent growth in lesions, compared with a median of less than 5 percent growth in lesions in Cerestat patients. ...